Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 05, 2021
An interview with Nancy Valente, the Global Head of Hematology Development at Roche.
Journal: Expert review of hematology
Published: July 21, 2020
Rituximab dosing in hematological malignancies: an old question, revisited.
Journal: Cancer chemotherapy and pharmacology
Published: January 02, 2019
Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience.
Journal: Advances in therapy
Published: July 14, 2017
Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 29, 2016
The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 18, 2016
PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia.
Journal: Blood
Published: June 12, 2014
Population pharmacokinetics of rituximab in patients with chronic lymphocytic leukemia.
Journal: Journal of clinical pharmacology
Published: January 12, 2012
Showing 1-8 of 8
Last Updated: 09/26/2026